Pre-clinically, we found that blocking the β2-AR signaling, STAT-3 signaling or ATP and Itaconate metabolites results in enhancement of doxorubicin chemotherapy, marked by reduced tumor growth and increased survival in the EL4 murine lymphoma model. The gene discussed is ADRB2; the disease is lymphoma.